WHY SHOULD YOU USE VANGUARD® DAPP?

Key Vaccine Benefits

1. Effective in the presence of maternal antibodies (MA), delivering early protection
2. Causes rapid onset of immunity; therefore, narrows the window of susceptibility
3. Effective against CPV-2c, giving protection against the predominant circulating strain

HIGH TITER
High-titer vaccines contain a higher number of virus particles per dose

LOW PASSAGE
Passaging is the process of culturing and harvesting successive generations of viruses with gradual loss of pathogenicity/virulence

Low-passage CPV is more immunogenic than higher-passage CPV

- Parvovirus is a significant threat for puppies
- CPV-specific MA titers may interfere with an active immune response, resulting in a “window of susceptibility”
- At low passage levels, the virus replicates well in tissue culture and in the dog, but is no longer pathogenic—an effective vaccine
- At higher passage levels, the remaining virus population may be so well adapted to the tissue culture environment that they fail to replicate or immunize well in dogs
- Vaccine parvovirus replication in the dog is essential in stimulating protective antibody production

EXCEPTIONAL SCIENCE. DEPENDABLE SUPPORT.
Do you know the CPV particles per dose of other vaccines?

Vanguard DAPP—over 10,000,000 CPV particles per dose.*

High-titer, Low-passage Parvo Antigen

• Reduce the “window of susceptibility” that has been the major cause of CPV vaccination failure

• The high-titer, low-passage vaccine virus in Vanguard Plus CPV is highly immunogenic and capable of stimulating active immunity in the presence of maternal antibodies (MA)

Seroconversion of puppies following vaccination with Vanguard Canine Parvo

67% 93% 100%

1st vaccination (6 weeks of age) 2nd vaccination (9 weeks of age) 3rd vaccination (12 weeks of age)

The effect of Maternal Antibodies

Levels of MA in puppies

MA below this level will not protect the puppy

Above this level, MA will interfere with vaccination

Higher-titer Vanguard® DAPP Vaccine overcomes higher levels of MA

Reduced window of susceptibility with Vanguard® DAPP

Window of susceptibility

In a 60-puppy study of (30) Vanguard Plus parvo vaccinates, all puppies seroconverted† within 21 days of a third vaccination at 12 weeks of age.*


Do you know the CPV particles per dose of other vaccines?

Vanguard DAPP—over 10,000,000 CPV particles per dose.*

High-titer, Low-passage Parvo Antigen

• Reduce the “window of susceptibility” that has been the major cause of CPV vaccination failure

• The high-titer, low-passage vaccine virus in Vanguard Plus CPV is highly immunogenic and capable of stimulating active immunity in the presence of maternal antibodies (MA)

Seroconversion of puppies following vaccination with Vanguard Canine Parvo

67% 93% 100%

1st vaccination (6 weeks of age) 2nd vaccination (9 weeks of age) 3rd vaccination (12 weeks of age)

The effect of Maternal Antibodies

Levels of MA in puppies

MA below this level will not protect the puppy

Above this level, MA will interfere with vaccination

Higher-titer Vanguard® DAPP Vaccine overcomes higher levels of MA

Reduced window of susceptibility with Vanguard® DAPP

Window of susceptibility

In a 60-puppy study of (30) Vanguard Plus parvo vaccinates, all puppies seroconverted† within 21 days of a third vaccination at 12 weeks of age.*
